A 46-year-old woman with type 2 diabetes on metformin 1g twice daily and gliclazide 160mg twice daily has an HbA1c of 69 mmol/mol (8.5%). Her BMI is 34 kg/m². She works as a heavy goods vehicle (HGV) driver. What is the most appropriate addition to her treatment?
Q52
A 73-year-old man with type 2 diabetes for 19 years presents with confusion. He has a background of hypertension and ischaemic heart disease. His wife reports he has been increasingly drowsy over 5 days with reduced oral intake. On examination: temperature 36.8°C, pulse 110/min, BP 95/60 mmHg, GCS 13/15. Blood tests show: glucose 62.4 mmol/L, sodium 158 mmol/L, potassium 4.8 mmol/L, urea 28.4 mmol/L, creatinine 198 μmol/L, osmolality 392 mOsm/kg. Venous blood gas: pH 7.38, bicarbonate 22 mmol/L. Urinalysis: glucose 4+, ketones negative. What is the most appropriate initial fluid resuscitation?
Q53
A 51-year-old woman presents with fatigue and is found to have TSH 74 mU/L (0.5-5.0) and free T4 6 pmol/L (10-22). She is started on levothyroxine 50 micrograms once daily. When should thyroid function tests be rechecked to guide dose adjustment?
Q54
A 29-year-old man with type 1 diabetes for 14 years is reviewed in clinic. He uses a basal-bolus insulin regimen with insulin degludec at night and insulin aspart before meals. His HbA1c is 82 mmol/mol (9.6%). He reports frequent episodes of hypoglycaemia, occurring 4-5 times per week, usually before lunch. His pre-breakfast glucose readings average 14-16 mmol/L. What is the most likely explanation for his elevated morning glucose levels?
Q55
What is the threshold HbA1c level (in mmol/mol) for diagnosing diabetes mellitus in an asymptomatic patient according to WHO and Diabetes UK criteria?
Q56
A 33-year-old woman is diagnosed with Graves' disease. Thyroid function shows TSH <0.01 mU/L, free T4 42 pmol/L, free T3 18.2 pmol/L. She is planning to conceive within the next 6 months. What is the most appropriate initial management?
Q57
A 68-year-old woman with type 2 diabetes for 16 years attends for diabetic foot screening. She has longstanding hypertension and stage 3 chronic kidney disease. On examination, both feet are warm with palpable pulses. Monofilament testing shows absent sensation bilaterally on the plantar surface. Ankle reflexes are absent. Vibration sense is reduced to the knees bilaterally. What is her foot risk classification according to NICE guidelines?
Q58
A 19-year-old woman with type 1 diabetes for 5 years presents to the emergency department with vomiting and abdominal pain. Blood tests show: glucose 28.4 mmol/L, pH 7.18, bicarbonate 11 mmol/L, ketones 5.2 mmol/L, sodium 131 mmol/L, potassium 5.8 mmol/L, urea 8.2 mmol/L, creatinine 98 μmol/L. She is started on fixed-rate insulin infusion and intravenous fluids. After 4 hours, repeat blood shows: glucose 18.2 mmol/L, pH 7.24, bicarbonate 13 mmol/L, potassium 3.6 mmol/L. What is the most appropriate next step?
Q59
A 57-year-old man with type 2 diabetes for 10 years presents with a 4-month history of progressive weakness, particularly when climbing stairs. He also reports erectile dysfunction and reduced libido. Examination shows proximal muscle weakness and reduced reflexes. HbA1c is 76 mmol/mol (9.1%). Thyroid function tests show TSH 0.2 mU/L (0.5-5.0), free T4 18 pmol/L (10-22), free T3 3.8 pmol/L (3.5-6.5). What is the most likely diagnosis?
Q60
A 42-year-old woman with type 2 diabetes is started on empagliflozin. She returns 2 weeks later with a 3-day history of urinary frequency, dysuria, and lower abdominal pain. Urine dipstick shows blood 2+, protein 1+, leucocytes 3+, and nitrites positive. Temperature is 38.2°C. She is haemodynamically stable. Blood glucose is 18.2 mmol/L. What is the most appropriate initial management?
Endocrinology & Diabetes UK Medical PG Practice Questions and MCQs
Question 51: A 46-year-old woman with type 2 diabetes on metformin 1g twice daily and gliclazide 160mg twice daily has an HbA1c of 69 mmol/mol (8.5%). Her BMI is 34 kg/m². She works as a heavy goods vehicle (HGV) driver. What is the most appropriate addition to her treatment?
A. Add sitagliptin 100mg once daily (Correct Answer)
B. Add pioglitazone 30mg once daily
C. Add dapagliflozin 10mg once daily
D. Add insulin glargine at bedtime
E. Add exenatide twice daily before meals
Explanation: ***Add sitagliptin 100mg once daily***
- **Sitagliptin**, a **DPP-4 inhibitor**, has a **low risk of hypoglycemia**, which is crucial for an **HGV driver** as severe hypoglycemic episodes can be dangerous and impact their driving license.
- It is **weight neutral**, making it a suitable choice for a patient with a **BMI of 34 kg/m²**, avoiding further weight gain, and can be easily added to existing dual therapy.
*Add pioglitazone 30mg once daily*
- **Pioglitazone** is known to cause **significant weight gain**, which would be detrimental for a patient with a **BMI of 34 kg/m²**.
- It is also associated with a risk of **fluid retention** and **heart failure exacerbation**, as well as a potential increased risk of **bladder cancer**, making it a less favorable option.
*Add dapagliflozin 10mg once daily*
- While **SGLT2 inhibitors** like **dapagliflozin** can promote **weight loss** and have cardiovascular/renal benefits, they can increase the risk of **genital candidiasis**, **urinary tract infections**, and **volume depletion**.
- Given the patient's occupation, agents that could cause **dehydration** or electrolyte imbalances, potentially affecting alertness, might be less desirable compared to a safer option for a third line agent.
*Add insulin glargine at bedtime*
- Initiating **insulin therapy** typically carries a higher risk of **hypoglycemia**, which would pose significant safety concerns and potential licensing issues for an **HGV driver** according to **DVLA regulations**.
- Insulin also commonly causes **weight gain**, which is undesirable in a patient with a **high BMI**.
*Add exenatide twice daily before meals*
- **GLP-1 receptor agonists** like **exenatide** are effective for weight loss and glycemic control, but they are administered via **injection**, which can be less convenient than an oral medication.
- They are also associated with **gastrointestinal side effects** like nausea and vomiting, which could impact the patient's quality of life and adherence, making a well-tolerated oral agent a better initial choice for triple therapy.
Question 52: A 73-year-old man with type 2 diabetes for 19 years presents with confusion. He has a background of hypertension and ischaemic heart disease. His wife reports he has been increasingly drowsy over 5 days with reduced oral intake. On examination: temperature 36.8°C, pulse 110/min, BP 95/60 mmHg, GCS 13/15. Blood tests show: glucose 62.4 mmol/L, sodium 158 mmol/L, potassium 4.8 mmol/L, urea 28.4 mmol/L, creatinine 198 μmol/L, osmolality 392 mOsm/kg. Venous blood gas: pH 7.38, bicarbonate 22 mmol/L. Urinalysis: glucose 4+, ketones negative. What is the most appropriate initial fluid resuscitation?
A. 0.9% sodium chloride 1000 mL over 1 hour (Correct Answer)
B. Hartmann's solution 1000 mL over 1 hour
C. 0.45% sodium chloride 1000 mL over 1 hour
D. 5% dextrose 1000 mL over 1 hour
E. 0.9% sodium chloride with 40 mmol/L potassium chloride 1000 mL over 1 hour
Explanation: ***0.9% sodium chloride 1000 mL over 1 hour***
- The patient presents with **Hyperosmolar Hyperglycaemic State (HHS)**, evidenced by severe **hyperglycaemia** (>30 mmol/L), **hyperosmolality** (>320 mOsm/kg), and lack of ketosis; the primary goal is restoration of circulating volume.
- **0.9% sodium chloride** is the recommended initial fluid for resuscitation in HHS, even in the presence of hypernatraemia, as it is relatively hypotonic to the patient's serum and prevents a rapid drop in osmolality.
*Hartmann's solution 1000 mL over 1 hour*
- While used in some resuscitation scenarios, it is not the standard recommendation for **HHS management** guidelines, which prioritize isotonic saline to stabilize intravascular volume.
- It contains **potassium and lactate**, which may complicate the fine-tuning of electrolyte balance required in the prolonged recovery phase of HHS.
*0.45% sodium chloride 1000 mL over 1 hour*
- **Hypotonic saline (0.45%)** is only considered if the serum osmolality is not declining despite an adequate positive fluid balance with 0.9% saline.
- Administering hypotonic fluids too early or too rapidly increases the risk of **cerebral oedema** and a precipitous drop in serum sodium.
*5% dextrose 1000 mL over 1 hour*
- Giving **5% dextrose** initially would worsen the existing severe **hyperglycaemia** and exacerbate the hyperosmolar state.
- Dextrose is only introduced in later stages of management once blood glucose levels have dropped to a specific threshold (e.g., 10-15 mmol/L).
*0.9% sodium chloride with 40 mmol/L potassium chloride 1000 mL over 1 hour*
- Aggressive **potassium replacement** is not indicated in the first hour of resuscitation when the serum potassium is within the normal range (4.8 mmol/L).
- Initial management focuses purely on **volume expansion**; potassium is usually added in subsequent bags once the patient is producing urine and levels begin to fall due to dilution or insulin.
Question 53: A 51-year-old woman presents with fatigue and is found to have TSH 74 mU/L (0.5-5.0) and free T4 6 pmol/L (10-22). She is started on levothyroxine 50 micrograms once daily. When should thyroid function tests be rechecked to guide dose adjustment?
A. After 2 weeks
B. After 1 week
C. After 4 weeks
D. After 8-12 weeks (Correct Answer)
E. After 6 months
Explanation: ***After 8-12 weeks***
- It takes approximately **6-8 weeks** for **TSH levels** to reach a new steady state and equilibrate after starting or changing the dose of **levothyroxine**.
- Testing within this window (8-12 weeks) provides the most accurate reflection of the patient's long-term thyroid status due to the long **seven-day half-life** of T4.
*After 2 weeks*
- This is too early for monitoring because the full therapeutic effect on the **pituitary-thyroid axis** will not have manifested yet.
- The **serum T4** levels may fluctuate, but the **TSH** will not yet have decreased significantly from its baseline high of 74 mU/L.
*After 1 week*
- At one week, the patient may feel slight symptomatic improvement, but the **steady-state concentration** of the drug is far from being achieved.
- Rechecking at this stage would likely lead to inappropriate **dose escalations** based on misleadingly high TSH results.
*After 4 weeks*
- Although some clinical guidelines may monitor at 6 weeks, 4 weeks is generally considered insufficient for full **TSH stabilization**.
- Adjusting doses at this point risks **over-titration** as the TSH is often still in a downward trend and has not bottomed out.
*After 6 months*
- This interval is too long for the initial titration phase where the patient remains profoundly **hypothyroid** (TSH 74 mU/L).
- Six-month or **annual monitoring** is reserved for stable patients who have already achieved a **euthyroid state** on a consistent dose.
Question 54: A 29-year-old man with type 1 diabetes for 14 years is reviewed in clinic. He uses a basal-bolus insulin regimen with insulin degludec at night and insulin aspart before meals. His HbA1c is 82 mmol/mol (9.6%). He reports frequent episodes of hypoglycaemia, occurring 4-5 times per week, usually before lunch. His pre-breakfast glucose readings average 14-16 mmol/L. What is the most likely explanation for his elevated morning glucose levels?
A. Insufficient basal insulin dose
B. Dawn phenomenon
C. Somogyi effect (Correct Answer)
D. Excessive carbohydrate intake at breakfast
E. Impaired insulin absorption
Explanation: ***Somogyi effect***
- This occurs when **nocturnal hypoglycaemia** triggers a surge in counter-regulatory hormones (glucagon, epinephrine, cortisol), leading to **rebound hyperglycaemia** in the morning.
- The combination of **frequent hypoglycaemia** and high pre-breakfast glucose readings (14-16 mmol/L) is classic for this rebound mechanism.
*Insufficient basal insulin dose*
- Insufficient basal insulin would typically cause high glucose readings throughout the entire day and night without causing **frequent hypoglycaemia**.
- It does not explain why the patient would experience hypoglycaemic episodes 4-5 times per week.
*Dawn phenomenon*
- This refers to a rise in early morning glucose due to the physiological release of **growth hormone** and **cortisol** that antagonize insulin, without preceding hypoglycaemia.
- Unlike the Somogyi effect, it is not preceded by **nocturnal hypoglycaemia**, which is likely present here given the patient's symptomatic history.
*Excessive carbohydrate intake at breakfast*
- High carbohydrate intake at breakfast would primarily affect **post-prandial glucose** readings rather than pre-breakfast (fasting) values.
- This does not account for the **high morning basal readings** or the frequent hypoglycaemia occurring before lunch.
*Impaired insulin absorption*
- **Lipohypertrophy** or impaired absorption would cause unpredictable and generally **elevated glucose levels** due to reduced insulin efficacy.
- It would not characteristically lead to this specific pattern of **recurrent hypoglycaemia** followed by morning spikes.
Question 55: What is the threshold HbA1c level (in mmol/mol) for diagnosing diabetes mellitus in an asymptomatic patient according to WHO and Diabetes UK criteria?
A. 58 mmol/mol (7.5%)
B. 64 mmol/mol (8.0%)
C. 42 mmol/mol (6.0%)
D. 48 mmol/mol (6.5%) (Correct Answer)
E. 53 mmol/mol (7.0%)
Explanation: ***48 mmol/mol (6.5%)***- According to **WHO** and **Diabetes UK** criteria, an HbA1c of **48 mmol/mol (6.5%)** or above is the standard threshold for diagnosing diabetes mellitus.- For **asymptomatic patients**, this result must be **confirmed with a repeat test** on a separate occasion to establish the diagnosis.*58 mmol/mol (7.5%)*- This level is significantly higher than the diagnostic threshold and is often used as a **target level** for intensifying therapy in patients already diagnosed.- It is not used as a threshold for initial diagnosis in clinical guidelines.*64 mmol/mol (8.0%)*- This value represents poorly controlled diabetes or a **higher glycemic target** for elderly patients or those with multiple comorbidities.- Using this as a diagnostic cutoff would result in a massive failure to diagnose **early-stage diabetes**.*42 mmol/mol (6.0%)*- An HbA1c between **42-47 mmol/mol (6.0-6.4%)** is classified as the **prediabetes** range or high risk for developing diabetes.- Levels below 42 mmol/mol are generally considered within the **normal/healthy range** for the general population.*53 mmol/mol (7.0%)*- This is a common **therapeutic target** for many adults with established type 2 diabetes managed with medication.- While it exceeds the diagnostic threshold, the actual **cutoff point** for diagnosis remains lower at 48 mmol/mol.
Question 56: A 33-year-old woman is diagnosed with Graves' disease. Thyroid function shows TSH <0.01 mU/L, free T4 42 pmol/L, free T3 18.2 pmol/L. She is planning to conceive within the next 6 months. What is the most appropriate initial management?
A. Carbimazole titration regimen
B. Carbimazole block-and-replace regimen
C. Propylthiouracil (Correct Answer)
D. Radioactive iodine therapy
E. Total thyroidectomy
Explanation: ***Propylthiouracil***
- **Propylthiouracil (PTU)** is the preferred antithyroid drug for women planning pregnancy or in the **first trimester** because it has a lower risk of causing major congenital malformations compared to carbimazole.
- The switch to PTU is critical for patients planning to conceive within **6 months** to avoid the risk of **carbimazole embryopathy**, which includes defects like aplasia cutis and esophageal atresia.
*Carbimazole titration regimen*
- **Carbimazole** is usually the first-line treatment for Graves' disease, but it is associated with a risk of **congenital abnormalities** during early fetal development.
- It is generally avoided in patients actively planning a pregnancy to minimize the risk of **teratogenicity** during the organogenesis phase.
*Carbimazole block-and-replace regimen*
- This regimen involves high-dose antithyroid drugs combined with **levothyroxine**, which is contraindicated during pregnancy as it requires higher doses of medications that can cross the placenta.
- Using **carbimazole** in this regimen still poses a significant risk of **embryopathy** for a patient planning to conceive soon.
*Radioactive iodine therapy*
- **Radioactive iodine (RAI)** is absolutely contraindicated in pregnancy and carries a strict recommendation to avoid conception for at least **6 months** following treatment.
- While it provides a permanent cure for **hyperthyroidism**, it would significantly delay the patient's goal of conceiving within the specified 6-month window.
*Total thyroidectomy*
- **Total thyroidectomy** is an invasive surgical option usually reserved for patients with large goiters, compressive symptoms, or those who fail medical therapy.
- While it allows for rapid stabilization of thyroid levels before pregnancy, it is not the **initial management** of choice for a newly diagnosed patient when medical options are available.
Question 57: A 68-year-old woman with type 2 diabetes for 16 years attends for diabetic foot screening. She has longstanding hypertension and stage 3 chronic kidney disease. On examination, both feet are warm with palpable pulses. Monofilament testing shows absent sensation bilaterally on the plantar surface. Ankle reflexes are absent. Vibration sense is reduced to the knees bilaterally. What is her foot risk classification according to NICE guidelines?
A. Acute diabetic foot emergency - immediate admission
B. Low risk - annual review indicated
C. Moderate risk - review every 3-6 months
D. High risk - review every 1-3 months (Correct Answer)
E. Active diabetic foot problem - specialist referral
Explanation: ***High risk - review every 1-3 months***
- According to **NICE guidelines (NG19)**, a patient is classified as high risk if they have **loss of protective sensation** (absent monofilament test) plus another risk factor such as **chronic kidney disease** (stage 4 or 5) or deformity.
- While her pulses are palpable, her combination of **sensory neuropathy** and **CKD** (medical risk factor) warrants frequent monitoring every **1-3 months** to prevent ulceration.
*Acute diabetic foot emergency - immediate admission*
- This category is reserved for patients with life-threatening complications like **gas gangrene**, **necrotising fasciitis**, or systemic sepsis.
- This patient is clinically stable with **warm feet** and no evidence of acute infection or critical ischemia.
*Low risk - annual review indicated*
- Low risk classification requires the **absence of any risk factors**, such as normal sensation and intact peripheral pulses.
- This patient has significant **neuropathy** and **CKD**, making an annual review insufficient for her safety.
*Moderate risk - review every 3-6 months*
- Moderate risk is assigned when there is only **one risk factor** present, such as isolated loss of sensation or isolated peripheral arterial disease.
- Because this patient has **multiple risk factors** (neuropathy and long-standing CKD/diabetes duration), she exceeds the criteria for moderate risk.
*Active diabetic foot problem - specialist referral*
- This classification applies to patients with an **active ulcer**, infection, suspected **Charcot arthropathy**, or gangrene.
- Although she is at high risk for these issues, her skin is currently intact with no **active ulceration** mentioned in the examination.
Question 58: A 19-year-old woman with type 1 diabetes for 5 years presents to the emergency department with vomiting and abdominal pain. Blood tests show: glucose 28.4 mmol/L, pH 7.18, bicarbonate 11 mmol/L, ketones 5.2 mmol/L, sodium 131 mmol/L, potassium 5.8 mmol/L, urea 8.2 mmol/L, creatinine 98 μmol/L. She is started on fixed-rate insulin infusion and intravenous fluids. After 4 hours, repeat blood shows: glucose 18.2 mmol/L, pH 7.24, bicarbonate 13 mmol/L, potassium 3.6 mmol/L. What is the most appropriate next step?
A. Continue current management and recheck in 2 hours
B. Add 10% glucose infusion and continue fixed-rate insulin (Correct Answer)
C. Reduce the fixed-rate insulin infusion rate by half
D. Stop fixed-rate insulin and start subcutaneous insulin
E. Increase the fixed-rate insulin infusion rate
Explanation: ***Add 10% glucose infusion and continue fixed-rate insulin***
- According to **DKA management guidelines**, 10% glucose should be added once blood glucose falls below **14 mmol/L** to prevent hypoglycemia while maintaining the insulin infusion needed to suppress **ketogenesis**.
- Although the glucose is currently 18.2 mmol/L, the rapid drop and the ongoing need for **fixed-rate intravenous insulin infusion (FRIII)** to clear ketones (acidosis is still present with pH 7.24) necessitate the addition of glucose soon to ensure the insulin rate is not decreased prematurely.
*Continue current management and recheck in 2 hours*
- Waiting 2 hours without intervention risks a further precipitous drop in glucose, as the **insulin infusion** remains at a fixed rate regardless of blood sugar levels.
- Active management of **potassium** and preparation for glucose administration are required as the patient approaches target glucose levels while still in **acidosis**.
*Reduce the fixed-rate insulin infusion rate by half*
- The **fixed-rate insulin** must remain constant (usually 0.1 units/kg/hr) to effectively switch off **ketone production** and resolve the metabolic acidosis.
- Reducing the insulin rate prematurely will delay the resolution of **ketoacidosis**, even if the blood glucose is improving.
*Stop fixed-rate insulin and start subcutaneous insulin*
- Transition to **subcutaneous insulin** is only appropriate when the DKA has resolved, defined by a **pH >7.3**, bicarbonate >15 mmol/L, and ketones <0.6 mmol/L.
- This patient is still **acidotic** (pH 7.24, bicarbonate 13 mmol/L), so stopping the IV infusion would lead to a rebound in **ketosis**.
*Increase the fixed-rate insulin infusion rate*
- The **biochemical markers** (pH and bicarbonate) are already improving, indicating that the current insulin dose is sufficient to treat the **ketoacidosis**.
- Increasing the rate would unnecessarily increase the risk of **hypoglycemia** and rapid electrolyte shifts, such as life-threatening **hypokalemia**.
Question 59: A 57-year-old man with type 2 diabetes for 10 years presents with a 4-month history of progressive weakness, particularly when climbing stairs. He also reports erectile dysfunction and reduced libido. Examination shows proximal muscle weakness and reduced reflexes. HbA1c is 76 mmol/mol (9.1%). Thyroid function tests show TSH 0.2 mU/L (0.5-5.0), free T4 18 pmol/L (10-22), free T3 3.8 pmol/L (3.5-6.5). What is the most likely diagnosis?
A. Subclinical hyperthyroidism
B. Diabetic amyotrophy
C. Primary hypothyroidism
D. Secondary hypothyroidism (Correct Answer)
E. Sick euthyroid syndrome
Explanation: ***Secondary hypothyroidism***
- The biochemical pattern of a **low TSH** (0.2 mU/L) alongside a **low-normal free T3** (3.8 pmol/L) and normal free T4 is diagnostic of **central (secondary) hypothyroidism**, indicating a failure of the pituitary gland to produce adequate TSH.
- The combination of **proximal muscle weakness**, **reduced reflexes**, **erectile dysfunction**, and **reduced libido** suggests multiple pituitary hormone deficiencies (**hypopituitarism**) affecting both thyroid and gonadal axes.
*Subclinical hyperthyroidism*
- This condition is defined by a **low TSH** with **normal free T3 and T4** levels but usually presents with subtle or no symptoms, or mild symptoms of thyroid hormone excess.
- It does not explain the presence of **proximal muscle weakness** (more typical of hypothyroidism) or symptoms of **hypogonadism** like reduced libido and erectile dysfunction.
*Diabetic amyotrophy*
- While it causes **proximal muscle weakness** in patients with diabetes, it typically presents with **severe thigh pain** and is often **asymmetric** in the early stages.
- It is a neurogenic complication of diabetes and would not account for the **low TSH** or the patient's **sexual dysfunction** symptoms, which point to an endocrine etiology.
*Primary hypothyroidism*
- In **primary hypothyroidism**, the TSH would be **elevated** as the pituitary attempts to compensate for a failing thyroid gland by increasing TSH secretion.
- The patient’s biochemical profile shows an **inappropriately low TSH**, which localizes the pathology to the **hypothalamus or pituitary** rather than the thyroid gland itself.
*Sick euthyroid syndrome*
- This is typically seen in patients with **severe acute illness** and usually features a **low T3** with a normal or low T4 and TSH.
- The **chronic presentation** (4-month history) of this patient’s symptoms and the associated features of **hypogonadism** make a primary pituitary lesion much more likely than a transient illness-related thyroid axis dysfunction.
Question 60: A 42-year-old woman with type 2 diabetes is started on empagliflozin. She returns 2 weeks later with a 3-day history of urinary frequency, dysuria, and lower abdominal pain. Urine dipstick shows blood 2+, protein 1+, leucocytes 3+, and nitrites positive. Temperature is 38.2°C. She is haemodynamically stable. Blood glucose is 18.2 mmol/L. What is the most appropriate initial management?
A. Continue empagliflozin and prescribe oral antibiotics
B. Stop empagliflozin temporarily and prescribe oral antibiotics (Correct Answer)
C. Stop empagliflozin permanently and prescribe oral antibiotics
D. Continue empagliflozin and admit for intravenous antibiotics
E. Stop empagliflozin temporarily and admit for intravenous antibiotics
Explanation: ***Stop empagliflozin temporarily and prescribe oral antibiotics***- SGLT2 inhibitors like **empagliflozin** promote **glycosuria**, which increases the risk of **urinary tract infections (UTIs)** and should be paused during acute illness to prevent dehydration and **euglycemic ketoacidosis**.- Since the patient is **haemodynamically stable** and lacks signs of systemic sepsis or pyelonephritis (e.g., flank pain, significant constitutional symptoms), **oral antibiotics** are the preferred first-line treatment for a symptomatic UTI.*Continue empagliflozin and prescribe oral antibiotics*- Continuing the drug during an active infection provides a **glucose-rich environment** in the urinary tract that may delay recovery or exacerbate the infection.- Failure to pause the medication increases the risk of **SGLT2-induced dehydration** and metabolic complications during an acute inflammatory state, such as **euglycemic DKA**.*Stop empagliflozin permanently and prescribe oral antibiotics*- **Permanent discontinuation** is generally not required for a single episode of UTI, as this is a manageable and known potential side effect of the drug class.- If infections become **recurrent** or severe (e.g., urosepsis), then a permanent switch to a different class of antidiabetic medication may be considered.*Continue empagliflozin and admit for intravenous antibiotics*- **Intravenous antibiotics** and admission are unnecessary because the patient is stable and does not present with **flank pain**, vomiting, or signs of **urosepsis**.- Continuing the SGLT2 inhibitor while the patient has a high fever and active infection is contraindicated due to the risk of **hypovolemia** and metabolic derangement.*Stop empagliflozin temporarily and admit for intravenous antibiotics*- Although stopping the medication is correct, admission is reserved for patients with **upper UTI (pyelonephritis)**, urinary obstruction, or those unable to tolerate oral intake.- Her symptoms of **dysuria** and **lower abdominal pain** suggest a lower UTI (cystitis), which can be managed safely in the outpatient setting with **oral therapy**.
